Carmell Corp files Axolotl Biologix H1 2023 financials: rev $21.9M, NI $1.8M

Longevity Health Holdings, Inc.

Axolotl H1 2023 revenue $21.9M (up 56% YoY from $14.0M) and net income $1.8M (up 57% from $1.2M).
Single customer (Customer A) and single product (Dualgraft) represent 100% of revenue.
Cash and equivalents $698k; accounts receivable $17.2M; inventory $2.6M.
Related-party loans from Burns Ventures $5.6M noncurrent; inventory purchases from Pinnacle $2.5M in H1 2023.
Operating cash flow negative $701k; cash decreased from $1.4M to $698k in H1 2023.

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.